EVERSANA Announces European Expansion
EVERSANA, a provider of next generation commercial services to the global life sciences industry, has opened a new office in London, UK to serve the company’s growing client and team needs.
Mike Ryan, Executive Vice President, EMEA, will be based at the London office, which includes experts across the company’s commercialization solutions.
Jim Lang, CEO, commented, “It’s our privilege to work with our clients across Europe—a region that continues to bring new innovations to market every day. Our teams have operated from Europe for many decades. As our world begins to come together in person once again, our London location is all about collaboration with each other and those we serve.”
The new location further accelerates EVERSANA’s position across Europe, which includes employees in 18 countries. The company has announced multiple commercialization agreements with European-based partners and clients. In 2021, the company also announced the expansion of medical information and integrated compliance services across Europe.
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.
